Podcasts about hrsa

This week's episode is a quick one. We pushed out this episode expecting to have HRSA guidance on rebate models to discuss, but we'll have to wait for that topic another day! Greg and Rob catch up on a few developments in the 340B news cycle, primarily recapping HRSA's first final agency action taken in the context of 340B ADR claims.  

Dr. Jennifer Carson joins host Ron Aaron and co-host Carol Zernial to talk about family care partnering values on this edition of Caregiver SOS.Special guest-cohost Tina Smith fills in for Carol Zernial! About Dr. Carson Jennifer Carson, PhD, is a Clinical Associate Professor and Founding Director of the Dementia Engagement, Education, and Research (DEER) Program at the University of Nevada, Reno (UNR), School of Public Health. Guided by a commitment to authentic partnerships, participatory research, and community-driven innovation, Jennifer leads efforts to inspire social change and lasting impact. Through the DEER Program, which houses Dementia Friendly Nevada, Jennifer collaborates with 9 community groups statewide to promote brain health, foster inclusive communities, and co-create innovative approaches to enhance dementia care, support, and well-being. In addition to Dementia Friendly Nevada, she and the DEER Program team partner on several other grant-funded initiatives, including Nevada’s CDC-funded BOLD Public Health Program, ACL-funded Dementia Support Specialist Program, and HRSA-funded Geriatric Workforce Enhancement Program. Jennifer’s pioneering work in transforming dementia care and support has earned her significant recognition, including the 2022 Mensa Foundation Laura Joyner Award and the 2024 UNR Foundation Established Innovator Award. Prior to joining the faculty at UNR, Jennifer worked as a professional care partner for nearly three decades and was also a family care partner—experiences that have profoundly shaped her values-driven scholarship, teaching, and approach. Hosts Ron Aaron and Carol Zernial, and their guests talk about Caregiving and how to best cope with the stresses associated with it. Learn about "Caregiver SOS" and the "Teleconnection Hotline" programs.See omnystudio.com/listener for privacy information.

Send us a textAmanda Klein-Cox joins me to talk about KinCarolina, a comprehensive support program for caregivers raising children with disabilities or special health care needs. The program combines peer support, training, financial assistance, and community-building to improve caregiver wellbeing and ultimately benefit the children in their care.• Kinship care occurs when relatives or close family friends raise children whose parents cannot care for them• For every child in formal foster care nationally, approximately 19 are in informal kinship care arrangements• In South Carolina, this ratio is even more dramatic—1:300• Most kinship caregivers receive little to no support despite saving states millions in foster care costs• Kinship caregivers face unique challenges including financial strain, legal barriers, and supporting children with trauma• Early results show caregivers feeling less isolated and better equipped to support their familiesAmanda's Bio:Amanda Klein-Cox, Ed.D., is a Senior Research Associate at the University of North Carolina at Chapel Hill, School of Social Work (SSW). Dr. Klein-Cox serves as the Project Implementation Manager for the KinCarolina program, which provides comprehensive support to kinship caregivers raising children with disabilities or special health care needs in the Midlands region of South Carolina. In addition to overseeing implementation, she organizes and convenes the project's Advisory Council and multi-state team of researchers and collaborators. She has also led developing and implementing a national survey of kinship caregivers with the same team. As a researcher, Dr. Klein-Cox is interested in bridging the fields of education and social work around child and family well-being, particularly in the area of kinship care. Since becoming a mom, she is also interested in the intersection of maternal mental health and well-being with child welfare and family well-being outcomes.  Dr. Klein-Cox owns Engage with Data and currently serves as the Lead Evaluator on the HRSA-funded Behavioral Health Workforce Education and Training program at Ohio State University.   Dr. Klein-Cox began her career as a middle school teacher. She earned a Doctorate of K-12 Education Leadership and Policy from Vanderbilt University. Contact Info for Amanda and KinCarolina:  kleincox@unc.eduwww.kincarolina.orgwww.facebook.com/kincarolinawww.linkedin.com/company/kincarolinaLike what you heard? Please like and share wherever you get your podcasts! Connect with Ann: Community Evaluation Solutions How Ann can help: · Support the evaluation capacity of your coalition or community-based organization. · Help you create a strategic plan that doesn't stress you and your group out, doesn't take all year to design, and is actionable. · Engage your group in equitable discussions about difficult conversations. · Facilitate a workshop to plan for action and get your group moving. · Create a workshop that energizes and excites your group for action. · Speak at your conference or event. Have a question or want to know more? Book a call with Ann .Be sure and check out our updated resource page! Let us know what was helpful. Music by Zach Price: Zachpricet@gmail.com

In this episode of the Pharmacy Innovators Podcast, host Jim Jorgenson is joined by two powerhouse voices in the 340B space: Kristin Fox Smith, Visante's own 340B expert, and Ted Slafsky, Publisher & CEO of the 340B Report. Together, they dive into the latest political and regulatory shifts shaking the 340B landscape — from new Congressional leadership and pending legislation to the major reorganization of HHS and HRSA. The episode also explores Medicaid trends, judicial developments, contract pharmacy access, and the broader political forces shaping healthcare access for vulnerable populations. Whether you're a healthcare leader, policymaker, or 340B stakeholder, this episode offers timely and valuable insights into the evolving landscape of the program. 340B Report website: https://340breport.com/ Subscribe now using coupon code VISANTE25

Health Resources & Services Administration (HRSA) audits of hospitals play a key role in ensuring compliance with 340B rules and regulations. In this episode, Dave Lacknauth, executive director of pharmacy services at Broward Health in Fort. Lauderdale, Fla., joins us to discuss the importance of taking a proactive, comprehensive approach to audit readiness with the goal of ensuring clean audit results. Compliance protects 340B accessBeing prepared for HRSA audits serves a crucial function that ultimately benefits the patients whom hospitals serve, Lacknauth explains. Maintaining the integrity of 340B means protecting access to 340B savings that hospitals can invest in crucial care for community members that need it. Continuous audit readinessLacknauth discusses how Broward Health maintains audit readiness by conducting internal audits, bringing in external consultants, and identifying areas of opportunity for improvement. A robust system of internal reviews means that when HRSA comes knocking, Broward Health is already prepared. This was evident after a recent audit of one of the system's hospitals that resulted in zero recommendations for improvement.Organization, resources, transparency are keyPreparing for audits requires a health system to invest time and resources, but Lacknauth stresses that these investments pay off. Engaging a comprehensive team from various departments in the audit readiness process allows for a health system to have the appropriate level of responsiveness and transparency during a HRSA audit.Resources:Nebraska Is 12th State To Enact Contract Pharmacy ProtectionsIdaho Becomes Fourth State To Mandate 340B Reports From Hospitals

Community DC Host Dennis Glasgow speaks with Dr. Sara Kinsman, Director from the Maternal and Child Health Bureau Staff - Division of Child, Adolescent, and Family Health at Her-Sa – also know as the Health Resources and Services Administration. We'll be spending the next 30 mins talking about Poison control – what you can do if a family member, friend, co-worker or someone you know has been poisoned and what you can do quickly do help them or yourself – we should mention that the poison help line is open 365 days a year 24/7 by simply calling 800 222 1222 

In this episode, Rob and Greg review tips and tricks for maintaining a covered entity's registration on the OPAIS database. Failure to keep an up-to-date and accurate listing on OPAIS can result in audit findings, and may warrant a corrective action plan with HRSA. The guys will cover some of the common compliance pitfalls with keeping an accurate record on this website. Megan from the team chimes in, too, with some tips for grantee covered entities. Register for our webinar to get CE for pharmacists and technicians: https://attendee.gotowebinar.com/register/7740801999245853530?source=340B+Unscripted

In this week's episode, Greg and Rob recap lessons learned from the recent 340B Coalition Winter Conference in San Diego. They'll share commentary that was circulating regarding HRSA audit trends, 340B rebate models, Inflation Reduction Act impact on budgets, contract pharmacy developments and some insights on what to watch for out of Washington D.C. Email us your questions at 340BUnscripted@spendmend.com!

On this episode, Rob and Greg are joined again by healthcare attorney Emily Cook. Emily shares some insight into CMS Provider Based Rules and how 340B covered entities need to be thoughtful about where these rules intersect with various 340B Program initiatives, including new outpatient service implementation, referral capture and pharmacist-driven medication management models. We are at 340B Coalition Winter Conference in San Diego, CA. Come visit us at booth #315 to talk with our team about hot topics in the 340B world, from patient definition to HRSA audits, to program optimization!

In this episode, Greg and Rob are joined again by Jeff Davis, healthcare attorney, to catch up on various court action impacting the 340B community. With so many 340B Program elements hung up in litigation, it's challenge to keep tabs on what has been happening. Jeff will recap key appellate court decisions on manufacturer-implemented restrictions of contract pharmacies, discuss the merits of litigation challenging state legislative efforts to protect contract pharmacy provisions, and share opinions on where 340B rebate models may go in the future. They'll also dive in to child site eligibility timing, HRSA-approved manufacturer, audits and recent threats to covered entities who receive in-kind funding. They'll also debate patient definition standards now that we are a year removed from the Genesis case.  We can't wait to see you at 340B Coalition Winter Conference in San Diego. Catch up with the SpendMend team at Booth #315.   

STFM President Joseph Gravel, MD, illustrates how he has staved off burnout by building a career around the life-giving practices of advocacy, service, and gratitude. Dr Gravel gives us a sneak peek into the strategic plan which will guide STFM in the coming years, centered around topics such as artificial intelligence (AI). He also lets us know about his dislike of the “P-Word” (“provider”) and why the labels used for family medicine professionals are so important to maintaining that professionalism which gives agency and appropriate voice to those giving relationship-based care in an era of corporatized medicine.Hosted by Omari A. Hodge, MD, FAAFP and Jay-Sheree Allen Akambase, MDCopyright © Society of Teachers of Family Medicine, 2025Resources:STFM Advocacy CourseProfessionalism in an Era of Corporate Medicine: Addressing Microlapses and Promoting Microacts as a New Model - Fam MedEmpowerment and the P-Word - Fam MedGet to Know Incoming STFM President Joseph Gravel, MD - STFM BlogGuest Bio:Joseph W. Gravel Jr., MD, FAAFPDr Gravel is Professor and Chair of the Department of Family and Community Medicine at the Medical College of Wisconsin in Milwaukee. During his 5+ years as Chair at MCW his department has created 3 new family medicine residency programs in Milwaukee (2) and Green Bay. He is a graduate of Tufts University School of Medicine in Boston and the Virginia Commonwealth University Fairfax Family Practice Center Family Medicine Residency. Dr Gravel served as a residency program director for over 20 years; he was founding residency program director of the Tufts University Family Medicine Residency in Malden, MA and was Chief Medical Officer and residency program director at the Greater Lawrence Family Health Center, a Teaching Health Center FQHC in Lawrence, MA.  He previously held teaching appointments at the University of Massachusetts Medical School (Worcester) and Tufts University School of Medicine (Boston).Dr Gravel is currently President of the Society of Teachers of Family Medicine (2024-25). He also serves on the Wisconsin Academy of Family Physicians' Board of Directors and as the senior Wisconsin Delegate to the AAFP Congress of Delegates. He is a Technical Advisor for the HRSA THCGME program. He is a Past President of the Association of Family Medicine Residency Directors (AFMRD), the Family Medicine Education Consortium (FMEC), and the Massachusetts Academy of Family Physicians. He has also served on the ABFM Board of Directors, the ACGME Review Committee for Family Medicine, the ADFM Finance Committee, the STFM Foundation Board of Trustees, and as Chair of the Academic Family Medicine Advocacy Committee. His department created Wisconsin's first HRSA-funded Teaching Health Center in 2023. His residency programs participated in 3 national residency innovation initiatives- the P4 National Demonstration Project, the HRSA Teaching Health Center program (one of the original 11), and the ACGME Length of Training (LoT) Pilot. He was selected by Governor Deval Patrick to serve as a Commissioner on the Massachusetts Special Commission on Graduate Medical Education, has been deeply involved in national and statewide primary care workforce issues, and received the 2013 STFM Advocate Award. www.stfm.org/stfmpodcast022025 

In what has become an annual tradition for the podcast, we consulted with 340B Health's expert staff to answer our listeners' most pressing 340B questions. As an uncertain and busy year starts for the world of 340B, we want to prepare you by covering your queries about the efforts by drug companies to impose 340B rebates, proposed federal and state legislation on 340B, how Inflation Reduction Act implementation will affect 340B, and more.340B Rebate Lawsuits Heat UpSo far, five drug companies have sued the Health Resources & Services Administration to challenge HRSA's rejections of their backend rebate proposals. 340B Health Vice President of Legal and Policy Amanda Nagrotsky notes that a rebate model would harm 340B hospitals through delayed access to 340B savings and potentially denials of legitimate rebate claims based on drugmaker interpretations of 340B rules. We recorded this episode just before 340B Health filed a motion to intervene as a defendant in the Johnson & Johnson (J&J) rebate lawsuit against HRSA.Lawmakers Eye Ways To Protect or Cut 340BThe new year means a new Congress and the start of new state legislative sessions. 340B Health Senior Vice President of Government Relations Tom O'Donnell notes that members of Congress have floated potential reductions in what the federal government pays for 340B drugs to help fund new spending priorities outside of health care, though it is unclear how seriously they are considering those options. 340B Health Vice President of Legal and Policy Greg Doggett reports that several states are considering new contract pharmacy or payment nondiscrimination protections for 340B hospitals, but others have introduced proposed new mandates for covered entities. Price Caps Will Apply to More Medicare DrugsThe list of drugs eligible for Medicare price caps will grow to 25 starting in 2027 under the Inflation Reduction Act, which will have implications for 340B savings on those drugs. 340B Health Research and Policy Analytics Manager Claudia Escue notes that popular weight loss and diabetes drugs like Ozempic and Wegovy have made the price cap list because of how much they cost Medicare. 340B Health is tracking how these price caps might lower 340B savings and have submitted letters to Medicare officials to represent other hospital concerns about the implementation of the IRA.Resources:340B Health Files Motion To Intervene in J&J Rebate LawsuitOption To Cut Commercial Pay Rates for 340B Drugs Is on Draft Congressional Budget “Menu”Medicare Expands List of Drugs Subject to Price Caps, Decreased 340B Savings340B Coalition Winter Conference Registration 

Elevated GP - www.theelevatedgp.com Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Peter Milgrom is Professor of Oral Health Sciences and Pediatric Dentistry in the School of Dentistry and adjunct Professor of Health Services in the School of Public Health at the University of Washington. He directs the Northwest Center to Reduce Oral Health Disparities. He holds academic appointments at Case Western University, University of Rochester, and University of California, San Francisco. He maintains a dental practice limited to the care of fearful patients and served as Director of the UW Dental Fears Research Clinic. Dr. Milgrom's work includes research on xylitol, the effectiveness of fluoride varnish and iodine in preschoolers, clinical efficacy and safety of diammine silver fluoride, motivational strategies to increase perinatal and well child dental visits in rural communities, and studies of cognitive interventions in pediatric and adult dental fear. The NIH, Maternal and Child Health Bureau, HRSA, and the Robert Wood Johnson Foundation support his work. Dr. Milgrom is author of 5 books and over 300 scientific articles. His latest book, Treating Fearful Dental Patients, was published in 2009.   Dr. Milgrom was Distinguished Dental Behavioral Scientist of the International Association for Dental Research for 1999. In 1999, and again in 2000, his work was recognized by the Giddon Award for research in the behavioral sciences in Dentistry. He received the Barrows Milk Award from IADR in 2000, recognizing his work for public health including the development of the Access to Baby and Child Dentistry (ABCD) program in Washington State. In 2003, Dr. Milgrom received a Special Commendation Award from the National Legal Aid and Defenders Association and the University of Washington Medical Center Martin Luther King, Jr. Community Service Award. In 2010, he received the Aubrey Sheiham Research Award for his work on xylitol. He serves on scientific review committees for the NIDCR, NIMHHD, NINDS, Center for Scientific Review at NIH and as a consultant to the FDA. In 2005, Dr. Milgrom was appointed the SAAD Visiting Professor of Pain and Anxiety Control at the King's College Dental Institute, University of London, UK for a six-year term. In 2008 he was awarded the degree of Doctor Honoris Causa from the University of Bergen, Norway in recognition of his work in social and behavioral dentistry. In 2012, he received the University of California, San Francisco Dental Alumni Gold Medal for his contributions to Dentistry. In 2012 he was also awarded the Norton Ross Award for Excellence in Clinical Research by the American Dental Association. In 2013, he was appointed to the Council of Scientific Affairs of the American Dental Association. In 2014, he received the Irwin M. Mandel Distinguished Mentor Award from the IADR. In 2015, he served as HMDP Expert in Dental Public Health for the Singapore Ministry of Health. Dr. Milgrom received his DDS from the University of California, San Francisco in 1972 and had a previous position at the National Academy of Sciences, Engineering, and Medicine. In the last few years, Dr. Milgrom has spoken to dental associations in Argentina, Colombia, Peru, Philippines, and USA and at major universities in USA and abroad.

In our first episode of 2025, Greg and Rob discuss the latest developments in 340B. They'll recap HRSA audit trends, discuss how Congressional committee membership seems to be forming, and discuss a variety of 340B provisions being litigated in court.

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Laura Cheever who was, until recently, the Associate Administrator of the HIV/AIDS Bureau at the Health Resources and Services Administration (HRSA). She joined HRSA in 1999 when she served as the national director of the Ryan White AIDS Education and Training Center program. Dr Cheever is Board Certified in Infectious Diseases and continues to provide clinical care for patients with HIV. Dr Cheever describes her early work at HRSA and the Ryan White HIV/AIDS Program. Dr Cheever and Dr Saag then discuss quality measures adopted to demonstrate program effectiveness and the impact these efforts had on funding. They also discuss the staff in the program and their role in working with local providers. They address the role that private insurance, the Affordable Care Act, and different presidential administrations play in the services of the program as well as work left to be done and look ahead to the next ten years of HIV care.0:00 – Introduction1:40 – A discussion of Dr Cheever's early years at the Health Resources and Services Administration (HRSA)7:51 – Implementation of national quality measures for HIV care using data collection through CAREWare11:41 – How did new information impact decision making regarding Ryan White funding decisions15:04 – Impact of changing guidelines on direction given to the Ryan White clinics19:26 – The staff at HRSA and the impact of potential budget cuts on the program24:05 – The role private insurance and the Affordable Care Act had in providing treatment through the Ryan White program 25:10 – Do different presidential administrations influence the services of the Ryan White program27:34 – Discussion of the work left to be done 29:29 – Predictions for the next ten years of HIV care and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Hosts Tod Ibrahim and David White are joined by Rachel Meyer, Strategic Policy Advisor to the Executive Vice President, to discuss the IOTA Final Rule, recent transplant legislation, and other end-of-year policy developments.

Hosts Tod Ibrahim and David White are joined by Rachel Meyer, Strategic Policy Advisor to the Executive Vice President, to discuss the IOTA Final Rule, recent transplant legislation, and other end-of-year policy developments.

In our last episode of 2024, Greg and Rob recap major developments in the 340B space from the last year.  They'll start with trends in HRSA audit activity, including thoughts on patient definition. They'll address a variety of manufacturer developments, from contract pharmacy restrictions to manufacturer audits to proposed 340B rebate models. They end with a forecast of what to watch for in 2025 Thank you for listening to our podcast! Email us at 340BUnscripted@spendmend.com if you have any questions or topics that you want us to address!

Earlier this year, the Health Resources & Services Administration took a strong stance against drug giant Johnson & Johnson's plan for a proposed 340B rebate model, but the fight over rebates is far from over. 340B Health President and CEO Maureen Testoni joins us to discuss how the company is taking the issue to federal court and how they are not the only drugmaker doing so.J&J Sues HRSA Over RebatesJ&J is arguing in court that HRSA lacks the authority to block a 340B rebate model. Such a model would allow individual drug companies effectively to impose their own rules on 340B drug purchases. These rules would curtail the number of drugs a company would offer a 340B discount on and reduce the number of patients that would be deemed 340B-eligible.Other Drugmakers Pushing RebatesBristol Myers Squibb and Eli Lilly also sued HRSA, claiming the agency does not have the authority to stop a rebate model. Sanofi has not yet filed suit but is saying it will impose its rebate scheme in early January. The Sanofi model raises significant concerns not just because of the imminent effective date but because it would impose far more stringent restrictions on 340B eligibility than HRSA ever has.State Contract Pharmacy Laws Rack Up More WinsIn another 340B issue before the federal courts, state contract pharmacy protections continue obtaining key litigation wins. Several district courts and one appeals court have upheld state laws designed to protect covered entity access to 340B pricing through community and specialty contract pharmacies.Resources:Brief Your Leadership on Drugmaker Rebate SchemesThe Wall Street Journal: “The Economic Imperative of Protecting 340B”Register for the 340B Coalition Winter Conference

In this season finale of AIM for Safer Birth, Christie is joined again by Dr. Veronica Gillispie-Bell to reflect on key themes from the season, including rural maternity care, collaborative models, and the structural barriers impacting maternal health. They discuss the realities of hospital closures, the importance of integrating community birth centers, and the critical need for sustainability in quality improvement efforts. Dr. Gillispie-Bell shares insights on bridging gaps across disciplines, tackling systemic inequities, and how to keep patients' goals at the center of care. Plus, they dive into the transformative power of data and the lessons that can guide future improvements. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

 In the last episode, you heard some of my testimony at the Texas Interim Legislature hearing on Scope of Practice. Today you're going to hear from a nurse practitioner, Holly Jeffries, who is practicing in rural Texas.Her testimony was particularly impactful and really quite persuasive to legislators. I think it's important to understand the NP point of view and also learn the concerns of legislators by listening to their line of questioning.Referenced in the podcast:Facts about NP primary care numbers (HRSA shows much fewer doing primary care than AANP represents): https://youtu.be/AqyUdQZ-9fYSupervising physicians sued without ever seeing or being consulted on a patient: https://www.medscape.com/viewarticle/990494?form=fpfhttps://youtu.be/GlfPSnHgC1Ahttps://www.jucm.com/supervising-doctors-may-be-held-liable-in-malpractice-suits/https://www.medpagetoday.com/meetingcoverage/acep/106708Increasing rates of malpractice and adverse reports for NPs: https://youtu.be/EOeGhR2uUSUPhysiciansForPatientProtection.org

In this week's episode, Greg and Rob cover the recent policy notice put out by Sanofi regarding a 340B credit model. They discuss how it compares to other proposed credit/rebate models, and more importantly how this one is unique. In the intro, the guys recap developments in Washington D.C., as well as some updates in court action amongst HRSA, covered entities and manufacturers regarding audit activity.

In this episode, Christie explores the intersection of substance use and maternal health with innovators Dr. Nichole Nidey and Michelle Kavouras, focusing on the power of lived expertise to shape equitable, evidence-based care. Dr. Nidey, a maternal and child health epidemiologist and founder of the Empower Project, discusses how her work collaborates with individuals who use substances during pregnancy to inform meaningful research and interventions. Michelle, a peer doula and harm reduction advocate, shares her journey from lived experience to leadership in substance use advocacy, highlighting the importance of compassionate, non-stigmatizing care. This conversation challenges misconceptions, unpacks the complexity of language in healthcare, and emphasizes the need to meet pregnant people where they are. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

The recent 2024 elections resulted in a new Trump administration and a Republican-controlled House and Senate. From policymakers to stakeholders across the industry, everyone is wondering what health policy will look like in 2025 and beyond. On this episode, Epstein Becker Green attorneys Ted Kennedy Jr., Leslie Norwalk, Philo Hall, and Alexis Boaz discuss the results of the 2024 elections and their impact on the health policy space. What will a second Trump administration look like? How might the election results affect the health care policies addressed during Congress's 2024 lame-duck session? Visit our site for related resources and email contact information: https://www.ebglaw.com/dhc84. Subscribe for email notifications: https://www.ebglaw.com/subscribe. Visit: http://diagnosinghealthcare.com. This podcast is presented by Epstein Becker & Green, P.C. All rights are reserved. This audio recording includes information about legal issues and legal developments. Such materials are for informational purposes only and may not reflect the most current legal developments. These informational materials are not intended, and should not be taken, as legal advice on any particular set of facts or circumstances, and these materials are not a substitute for the advice of competent counsel. The content reflects the personal views and opinions of the participants. No attorney-client relationship has been created by this audio recording. This audio recording may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules. The determination of the need for legal services and the choice of a lawyer are extremely important decisions and should not be based solely upon advertisements or self-proclaimed expertise. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers.

In this episode, Greg and Rob are joined by Rodney Whitlock, healthcare policy expert, to discuss the recent 2024 election results.    They'll discuss what the second Trump Administration might prioritize in terms of healthcare policy, how a Republican-controlled Congress will impact 340B legislation activity, and whether or not any developments coming out of the upcoming lame-duck session might be on the horizon for 340B providers. In the intro, Greg and Rob catch up on a variety of topics, including J&J's recently filed lawsuit against HRSA regarding rebate models, CMS final rules around inflation rebate penalties, and they share some anecdotes from recent HRSA audit activity.   Register for our upcoming webinars below: 340B Hidden Strategies: Mastering 340B Advocacy: https://attendee.gotowebinar.com/register/8182646241351674200?source=340B+Unscripted   The Power of Trulla: An Overview of Our Award-Winning Pharmacy Procurement Software: https://attendee.gotowebinar.com/register/8037692126057457751?source=340B+Unscripted  

Christie's talking with Audra Summers and Ashley Rainey about Indiana's innovative use of the AIM Patient Safety Bundles to drive sustainable change in maternal care. Audra and Ashley share their experiences implementing and maintaining quality improvements across Indiana's 75 delivery facilities. They discuss the importance of collaboration, the integration of safety measures into daily practices, and how sustainability is achieved through data-driven methods and cultural shifts. Tune in to learn how Indiana's approach to quality improvement can inspire and inform efforts nationwide. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

In this episode, we talk with Dr. Carey Eppes and her colleague, CheyAnne Harris, to explore Texas's experience with implementing the Maternal Early Warning Signs (MEWS) in maternal health care. Dr. Eppes shares her background and journey into the world of maternal health, detailing the personal motivations that drive her passion for this work. She and CheyAnne delve into the reasons behind adopting MEWS, how it was implemented, and the challenges faced along the way. This episode highlights the key levers that facilitate successful implementation and reveals the one thing for healthcare providers looking to adopt MEWS in their own practice. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

In this enlightening episode, we welcome Dr. Kathy MacLaughlin, an Associate Professor of Family Medicine at the Mayo Clinic, to discuss the transformative potential of self-collection for cervical cancer screening. Dr. MacLaughlin explains how this innovative method differs from traditional screening processes and shares the latest FDA-approved options available to patients. We review the current research, examining the accuracy and effectiveness of self-collection through large-scale studies and its successful implementation in other countries. The conversation also highlights the public health implications, including how self-collection can empower individuals, enhance access to screening in underserved areas, and ultimately reduce cervical cancer rates. Join us as we explore the future of cervical cancer screening and the critical role of community engagement in promoting this life-saving approach. Did you connect with this episode? Share your thoughts with us on social media using #CervivorPodcast or by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠emailing us.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠   For more Cervivor-related content, check out: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cervivor.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Cervivor on all social media platforms. If you would like to be interviewed as a potential guest for an upcoming episode or would like to request a speaker or topic for a future podcast episode, email us at info@cervivor.org. More About The Guest: Dr. Kathy MacLaughlin is an Associate Professor of Family Medicine at Mayo Clinic with a passion for cervical cancer elimination. She co-chairs the HPV Self-Collection work group for the American Cancer Society National Roundtable on Cervical Cancer and previously co-chaired the IT/EHR group for their Primary HPV Screening Initiative. She has served as a subject matter expert for NORC in their work with the Federal Cervical Cancer Collaborative on the Cervical Cancer Moonshot℠ Roundtable Series and with HRSA's Office of Women's Health Cervical Cancer ECHO Learning Series for Safety-Net Settings. --- Support this podcast: https://podcasters.spotify.com/pod/show/cervivor/support

Within the past few weeks, drugmaker Johnson & Johnson went head-to-head with 340B hospitals and the federal government over the company's plan to stop paying upfront 340B discounts on two of its top-selling drugs. 340B Health Senior Counsel Amanda Nagrotsky joins us to explain how that conflict played out.HRSA Warns Johnson & Johnson of Strong Punitive ActionsIn letters to J&J, the Health Resources & Services Administration (HRSA) warned the drugmaker that replacing 340B rebates with discounts only would be allowed if approved by the Health and Human Services (HHS) secretary. HRSA gave the company until the end of September to announce that it was going to walk away from its plan or face both civil monetary penalties and the termination of its pharmaceutical pricing agreement (PPA). Nagrotsky said the threat to end the PPA was unprecedented, noting that it would cause the company to lose access to Medicaid and Medicare Part B coverage for all its drugs.Johnson & Johnson Backs Down Under PressureJ&J announced at the end of September that it would walk back its plan to implement rebates in mid-October, bowing to pressure from federal health officials and a bipartisan group of nearly 200 members of Congress who opposed the J&J strategy. The company maintained that it disagreed with HRSA's reasoning and noted that it was reserving all legal rights with respect to rebates. That stance indicates the company is likely to continue its push to implement rebates.The Battle Against Rebates ContinuesDespite the win for hospitals on the J&J rebate scheme, efforts from the drug industry to change the 340B discount structure continue. Drug industry consultant Kalderos is part of ongoing litigation in a federal court in Washington, D.C., over the right to impose rebates. HRSA's references to the concept of HHS approval of rebate proposals also leaves open the door for companies to seek federal consent for such a model.Resources340B Hospitals Prevail on J&J Rebate Plans, But Fight Is Not OverBipartisan U.S House Letter to HHS, Sept. 27 HRSA Letter to Johnson & Johnson, Sept. 27J&J Response to HRSA, Sept. 30

Host Tod Ibrahim is joined by Rachel Meyer, Strategic Policy Advisor to the Executive Vice President and Suzanne Watnick, ASN Policy Scholar in Residence to discuss the recent developments in the transplant policy realm.

Host Tod Ibrahim is joined by Rachel Meyer, Strategic Policy Advisor to the Executive Vice President and Suzanne Watnick, ASN Policy Scholar in Residence to discuss the recent developments in the transplant policy realm.

In this episode, Christie talks with renowned maternal health expert Dr. Elliott Main. A pioneering figure in maternal mortality review and quality care initiatives, Dr. Main discusses the history and evolution of the Alliance for Innovation on Maternal Health (AIM). Together, they explore the challenges and triumphs of addressing severe maternal morbidity and mortality in the U.S., the early groundwork that led to AIM, and the collaborative efforts that turned ideas into actionable tools, such as life-saving AIM bundles. Dr. Main also shares his thoughts on the future of maternal health and the "one thing" he believes is critical to driving change moving forward. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

In this episode, Greg and Rob get back to 340B basics and have a conversation around the concept of “clean site” 340B-only locations.  They discuss what “clean site” means in the world of 340B, what the benefits of the approach are, what some of the risks and obstacles are from a compliance perspective, and share some anecdotes from past experiences working with these types of 340B universes. In the intro, the guys discuss a couple of recent developments – most notably, J&J's response to HRSA's enforcement letter regarding the proposed rebate model.   Register for our upcoming webinar "Revolutionizing Pharmacy Procurement: Unlocking Savings with Automated NDC Selection": https://attendee.gotowebinar.com/register/1835792334721804630?source=340BUnscripted

In this episode, Greg and Rob catch up on developments surrounding the J&J 340B rebate proposal, including HRSA's response. They'll address some outstanding questions from the recent SpendMend webinar on the topic. In the intro, they recap some updates regarding contract pharmacy litigation and thoughts on how DSCSA and product serialization data might impact 340B operations. If you missed it before, you can watch our webinar on the J&J 340B rebate model here: https://ww2.spendmend.com/webinar-jj-340b-rebate-model-what-covered-entities-need-to-know/

Christie is talking with Amy Romano, founder and CEO of Primary Maternity Care. Amy, a nurse midwife with an MBA, shares her experience blending clinical expertise with system-level healthcare leadership to revolutionize maternity care in rural communities. They discuss the critical role of freestanding birth centers, their capacity to offer low-risk, community-based care, and how these centers could be a key part of the solution to the growing issue of maternity deserts. Amy also dives into the challenges of regulatory barriers, the importance of risk-appropriate care, and the unique quality improvement strategies needed for safe community births. From pandemic-driven innovations to rethinking the future of rural maternity care, this episode is packed with actionable insights for improving maternal health outcomes in underserved areas.  This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Amazon has partnered with Talkspace to expand its digital health benefits program, which also includes Omada Health. Community Health Systems (CHS) subsidiary is acquiring 10 urgent care centers, following in the footsteps of other for-profit health systems. Steward Health Care auctioned off Glenwood Regional Medical Center for $500,000, but there are concerns about the continued involvement of hospital landlord Medical Properties Trust in operations. The text also includes sponsored content on safeguarding healthcare against ransomware and cybercrime, as well as information on trends in telehealth and strategies for improving provider data accuracy for payers. Healthcare Dive provides news and insights for healthcare leaders and is a publication operated by Industry Dive.Roivant's subsidiary, Dermavant, is being acquired by Organon, giving Organon access to a psoriasis and eczema cream called Vtama. This acquisition will provide Roivant with additional cash to fund its research and development plans. Meanwhile, biotech M&A activity has plateaued, with private company acquisitions continuing while public company acquisitions have slowed down. One biotech, Ratio Therapeutics, backed by Bristol Myers Squibb, is optimistic about the boom in radiopharma and the pharmaceutical industry's shift towards targeted radiation drugs. In other news, Novartis' Kisqali has received expanded FDA approval which could double its market for breast cancer treatment. Additionally, Express Scripts is suing the FTC over a report critical of pharmacy benefit manager business practices. The industry is also exploring new ways to deliver genetic therapies and improve clinical trial execution through systems thinking. Overall, the biopharma industry is experiencing exciting times with various developments and advancements in drug development and healthcare technology.Zimmer has decided to pull its hip implant off the market due to fracture risk, with plans to phase out its use by December. Merit Medical has acquired Cook's lead management business for $210 million, adding devices used in heart rhythm device procedures to its portfolio. Synchron has connected brain-computer interface technology to Amazon Alexa, allowing patients to control various functions without using their hands or voice. Senseonics has received FDA clearance for a one-year continuous glucose monitoring system, and Boston Scientific has closed its acquisition of Silk Road Medical. The wearables market is expected to grow by 13% annually between 2024 and 2030, highlighting the importance of adhesives in wearable device development. AI is increasingly influencing the value chain of medical device companies, and manufacturers are exploring ways to utilize AI throughout the product lifecycle. These developments reflect the ongoing innovation and evolution within the medtech industry.Roivant has sold Dermavant to Organon in a deal worth up to $1.2 billion, allowing Roivant to focus on their autoimmune-focused Immunovant and upcoming trials. Summit Therapeutics' bispecific for non-small cell lung cancer has shown promise against Keytruda but still needs more data. Other news includes the FDA approving Keytruda for pleural mesothelioma, Bernie Sanders claiming generics companies can offer a cheaper alternative to Ozempic, Novartis expanding Kisqali's use in breast cancer, and HRSA threatening sanctions against J&J. In the world of enzyme development, SignalChem Biotech offers tailored services. Additionally, new gene therapies for sickle cell disease are reaching patients, and the race for an obesity pill is heating up among companies like Novo, Roche, and Terns.The FDA is facing challenges with conducting overseas drug manufacturing inspections, with 42% of registered plants overdue for inspections. Indian drugmaker Zydus Lifesciences received a warnin

In this episode, Christie sits down with Dr. Andrea Greiner, a maternal-fetal medicine specialist at the University of Iowa, to discuss the unique challenges of rural maternity care. Dr. Greiner shares her experiences working at a perinatal regional center, offering insight into how larger facilities can support rural hospitals and providers. Together, they explore the importance of individualized care, the complexities of coordinating care across diverse healthcare settings, and the logistical hurdles rural patients face. Tune in for a discussion on improving access and quality of maternity care in rural America. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

In part two of our conversation with Dr. Tina Pattara-Lau, Maternal and Child Health Consultant at the Indian Health Service (IHS), Christie continues to explore the ongoing transformation of maternal health care within rural communities. Dr. Pattara-Lau delves deeper into the impact of culturally responsive care, the integration of traditional practices, and the expansion of telehealth services. They further discuss the strides being made in overcoming access barriers, fostering community trust, and implementing innovative care models tailored to the unique needs of American Indian/Alaska Native populations.  This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

In this episode, Greg and Rob are joined by healthcare attorney Todd Nova to discuss a proposed rule change put forth by CMS in 2023 regarding the Medicaid Drug Rebate Program (MDRP), which includes a potential change to the definition of “covered outpatient drug”. They'll discuss how covered entities have historically interpreted the definition of covered outpatient drugs, and what impact might come from CMS's proposed change in this definition. Greg and Rob also get Todd's take on recent HRSA audit activity in a post-Genesis 340B environment. In the intro, the guys discuss the recent announcement of Medicare prices on the first 10 drugs subject to IRA-mandated drug price negotiations, a court ruling in Texas over DSH% calculation and use of Section 1115 waiver days, and changes to claims submission via 340B ESP. 

In this episode of the Friends of NPACE Podcast we are joined by Dr. Leanne Fowler DNP, MBA, APRN, AGACNP-BC, CNE, FAANP, FAAN! This discussion focuses on the HRSA grant project LSU has undertaken to help educate nurses to be educators. We discuss the importance of educating nurse educators, the results thus far from the project, and how to access these great educational resources! Tune in every other Wednesday for new episodes of the Friends of NPACE Podcast on your favorite streaming platform (Spotify, Apple Music, YouTube, and the NPACE Learning Center).

In this episode of the Friends of NPACE Podcast we are joined by Dr. Leanne Fowler DNP, MBA, APRN, AGACNP-BC, CNE, FAANP, FAAN! This discussion focuses on the HRSA grant project LSU has undertaken to help educate nurses to be educators. We discuss the importance of educating nurse educators, the results thus far from the project, and how to access these great educational resources! Tune in every other Wednesday for new episodes of the Friends of NPACE Podcast on your favorite streaming platform (Spotify, Apple Music, YouTube, and the NPACE Learning Center).

Christie is delving into the unique challenges and innovative solutions in rural and Indigenous maternal health care with Dr. Tina Pattara-Lau, Maternal and Child Health Consultant at the Indian Health Service (IHS). Dr. Pattara-Lau shares her experiences and insights on improving patient access to quality care through culturally safe practices, partnerships, and innovative models such as telehealth and community-based care. They discuss the systemic barriers, the importance of culturally safe practices, and the role of community partnerships in enhancing care for American Indian/Alaska Native populations, emphasizing the need for continuous quality improvement and sensitivity to cultural and traditional practices. This show is brought to you by the Alliance for Innovation on Maternal Health (AIM). Join us in the journey toward safer, more equitable maternal care and learn more about AIM at saferbirth.org.This podcast is supported by the Health Resources and Services Administration, HRSA, of the United States Department of Health and Human Services, HHS, as part of an initiative to improve maternal health outcomes.

Today's Guest: Venchele Saint DicI am a Public Health Analyst at HRSA with 16 years of experience in public health policy, program management, and population health research in healthcare settings. I have worked with non-profits, academic institutions, and human rights nonprofits in the US and Senegal. I lead workgroup projects to support healthcare access in national and local community health centers nationwide. I manage a portfolio of 96 grantees (of $50 million) nationwide to deliver quality care to vulnerable populations. I have influenced healthcare through policy work such as analyzing new and proposed legislation and regulations to determine the impact on HRSA health center program operations and collaborating on the PH WINS nationally representative survey of the governmental public health workforce. I was also elected to the Delta Omega Honorary Society of Public Health at the Gamma Zeta Chapter in the University of Maryland School of Public Health in May 2022. My applied research resulted in 2 background papers (elderly persons and activities of daily living and transportation barriers among Medicare beneficiaries). I served in Peace Corps in Senegal as a Community Health Extension Agent. I have written more than 20 reports and white papers on social justice, racism, and health equity, as well as blog posts and other social media articles. I am a native in French and Haitian-Kreyol, and I have an intermediate proficiency level in Spanish. I have limited proficiency in Mandinka.Episode Quotes:"Regardless of what your writing project is, you have to be part of the process. A coach doesn't mean you're not involved anymore." -Venchele Saint Dic"You will rarely regret being authentic. It's better to know if your personality doesn't align with a client early on in the process." -Amber Fuhriman"When you publish a book. It is your product. It is your brand." -Venchele Saint Dic"What makes art so beautiful is knowing it will be perceived differently by people." -Amber FuhrimanFind Amber on Instagram: https://www.instagram.com/amberraefuhrimanVenchele Saint Dic:https://www.instagram.com/pathwaycoachwriting?igsh=YTA5YTdqZzRkeW0=https://www.instagram.com/venchelesaintdic?igsh=cWNrbnVsd3RyN2lnhttps://www.linkedin.com/in/venchele-saint-dic-drph-student-mph-baph-70480811/If you are interested in connecting with Amber, send an email to amber@amberfuhriman.com.Connect with other incredible people looking to break out of the corporate mindset by joining the Facebook Success Center: http://bit.ly/2MuWn53Checkout Amber's Speaker Reel: https://www.youtube.com/watch?v=vPj5OBvjrr0Schedule a connection call with Amber: https://calendly.com/amberfuhriman/connection-call?month=2021-05If you are interested in connecting with Amber, send an email to amber@amberfuhriman.com. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Greg and Rob have another repeat guest!  Healthcare attorney Emily Cook shares some insights gained from the 340B Coalition Summer Conference around recent HRSA audit patterns (08:37) and a cluster of manufacturer audits of 340B covered entities (27:46). In the intro, the guys touch base on some 340B newsworthy developments in the contract pharmacy and legislative space. Email us your 340B-related questions at 340BUnscripted@spendmend.com

Kristi Henderson is a healthcare leader, digital health pioneer, and clinician who advanced from a practicing nurse practitioner to CEO and is recognized as an industry thought leader for technology-forward healthcare companies. She has a proven track record of optimizing and executing profitable growth strategies, driving strong business operations, and leading differentiated clinical products and services. She is a cultivator of high-performing teams with a keen understanding of drivers of growth, profitability, and equity value creation, who also fosters a civic-minded culture resulting in a high level of collaboration and commitment. She is experienced in leading and scaling high-growth companies and owning & driving P&L results in geographically dispersed, multi-state, multi-site businesses. She boasts health leadership experience in academic and national nonprofit health systems as well as big tech and public pay/provider organizations, including two Fortune 5 companies.  She is the CEO of Confluent Health, a national value-based musculoskeletal health company, where she is responsible for expanding their nationwide services through the growth of community-based physical therapy clinics, workplace services, and virtual/digital solutions using the highest skilled therapists and innovative clinical pathways that optimize the latest in personalization and technology. ​ She was most recently the CEO of MedExpress and Optum Virtual Medical Group at United Health Group with former leadership roles at Amazon, Ascension Health, and the University of Mississippi Medical Center. She has a proven track record of delivering successful programs at scale that improve health and save money. She is known for her ability to execute and sustain these models in advance of them becoming an industry standard as evidenced by her first launch of a telehealth program in 2003 which is recognized as one of only two of HRSA's Centers of Excellence. She is the immediate past chair for the American Telemedicine Association. She is a Fellow in the American Academy of Nursing and remains active in healthcare education providing guest presentations and serving as an adjunct faculty member. She is an honorary Dean at the University of Washington School of Nursing and an adjunct faculty member in Population Health at the Dell Medical School at the University of Texas-Austin.She has testified before multiple U.S. Senate committees and given numerous presentations across the country, including a TEDx talk, to advance telehealth policy and share innovative new models of care. A few of her other leadership roles include service as an executive board member for the Association of American Medical Colleges Telehealth Committee, advisor for the National Quality Forum's telehealth committee and co-chair of the Telehealth Committee for the American Nurses Association. Henderson received her Doctor of Nursing Practice degree from the University of Alabama at Birmingham where she was recognized as the 2019 Distinguished Alumna from the School of Nursing. She maintains national certification as a family and acute care nurse practitioner.

While telehealth services were more commonly utilized during the pandemic, it seems like the telehealth era is just beginning. Let's Get Moving Host Maria Shilaos speaks with CAPT Heather Dimeris, Director for the Office for the Advancement of Telehealth (OAT) in HRSA, to learn how the new developments in telehealth are improving the way health care is being provided to patients nationwide. Instagram: @movingmaria Facebook: Let's Get Moving with Maria Website: https://linktr.ee/letsgetmovingwithmaria

In this episode, Greg and Rob are joined by a new SpendMend team member – Nick Gnadt – to discuss considerations around the use of alternate distribution models (ADMs) in the 340B space. They discuss some of the practical considerations around implementing ADM, where there may be operational or regulatory challenges, and what the long-term outlook is for this more novel strategy. In the intro, the guys recap a flurry of updates in contract pharmacy restrictions, and discuss a communication posted on OPA's website that foreshadows what might be an increasing number of HRSA audit reports released over the next few months that have findings of non-compliance. Catch us at 340B Coalition Summer Conference July 8th - 10th in National Harbor. We will be at booth 717! 

We explore pharmacy expansion and equitable health services access with our guests, Tina Plett-Kalainoff and Sarah Brondyke from Community Health Care, Inc. Discover how their collaborative efforts streamline pharmaceutical needs within healthcare systems to improve patient outcomes. We also chat about the vital role of vaccine and medication inventory management, and discuss strategies that enhance operations. Our conversation also touches on stories from the field and how current community health center expansion is combating pharmacy deserts to ensure equitable healthcare access for all.

In this episode, Greg and Rob continue to provide insights on the HRSA data request list.   DRL #8 is self-disclosure documentation and DRL #9 is Medicaid billing information, which includes providing details regarding your CE's listing on the Medicaid Exclusion File, as well as sample billing claim forms for physician-administered drugs and billing claim screenshots for retail dispenses. In the intro, they recap state-level 340B legislation, discuss ongoing uncertainty around Medicare Advantage & Part B underpayment remedies, and also note some recent data published on drug shortages. Rob and other folks from our team will be attending Asembia in Las Vegas from April 29 – May 2.  Reach out to us if you want to connect there! Email us at 340Unscripted@spendmend.com Also, save the date for our next webinar, which will be on May 14, 2024 – We'll be sharing tips on what covered entities should be doing to effectively self-audit their 340B Program operations!

SpendMend colleagues Jasmine and Megan continue their conversation providing some grantee CE perspectives concerning the HRSA DRL.